Abstract
In hypertensive patients with concomitant obesity observed decrease in activity of dopaminergic system in conjunction with increased activity of the renin-angiotensin-aldosterone system. Identified changes point to the advisability of appointing this group of patients the dopamine receptor agonist - bromocriptine-KV and antagonist of aldosterone - veroshpiron. As a result of treatment was an increase in dopamine levels in the urine, a decrease of aldosterone in the blood, normalization of the daily blood pressure monitoring.
MeSH terms
-
Adult
-
Aged
-
Aldosterone / blood
-
Blood Pressure / drug effects*
-
Bromocriptine / therapeutic use*
-
Dopamine / urine
-
Dopamine Agonists / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Male
-
Middle Aged
-
Mineralocorticoid Receptor Antagonists / therapeutic use*
-
Obesity / complications
-
Obesity / drug therapy*
-
Obesity / physiopathology
-
Receptors, Dopamine / metabolism
-
Renin-Angiotensin System / drug effects
-
Spironolactone / therapeutic use*
Substances
-
Dopamine Agonists
-
Mineralocorticoid Receptor Antagonists
-
Receptors, Dopamine
-
Spironolactone
-
Bromocriptine
-
Aldosterone
-
Dopamine